Relamorelin
- Generic Name
- Relamorelin
- Drug Type
- Small Molecule
- Chemical Formula
- C43H50N8O5S
- CAS Number
- 661472-41-9
- Unique Ingredient Identifier
- BIW199E18V
- Background
Relamorelin has been investigated for the treatment and basic science of Gastroparesis, Gastric Motility, Diabetes Mellitus, Parkinson's Disease, and Chronic Constipation, among others.
Diabetic Gastroparesis Study 05
- First Posted Date
- 2018-12-26
- Last Posted Date
- 2021-12-15
- Lead Sponsor
- Allergan
- Target Recruit Count
- 202
- Registration Number
- NCT03786380
- Locations
- 🇺🇸
Rocky Mountain Diabetes and Osteoporosis Center, PA, Idaho Falls, Idaho, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Preferred Primary Care Physicians, Inc., Pittsburgh, Pennsylvania, United States
Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02
- Conditions
- GastroparesisDiabetes Mellitus
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-02-08
- Last Posted Date
- 2021-08-06
- Lead Sponsor
- Allergan
- Target Recruit Count
- 311
- Registration Number
- NCT03426345
- Locations
- 🇺🇸
Atlanta Diabetes Associates, Atlanta, Georgia, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸The Ohio State University, Wexner Medical Center, Columbus, Ohio, United States
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03
- Conditions
- GastroparesisDiabetes Mellitus
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2021-12-22
- Lead Sponsor
- Allergan
- Target Recruit Count
- 467
- Registration Number
- NCT03420781
- Locations
- 🇺🇸
Gastroenterology Associates of Fairfield County, P.C., Bridgeport, Connecticut, United States
🇺🇸Applied Research Center of Arkansas, Little Rock, Arkansas, United States
🇺🇸Kindred Medical Institute for Clinical Trials, LLC, Corona, California, United States
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04
- Conditions
- GastroparesisDiabetes Mellitus
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-12-26
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- Allergan
- Target Recruit Count
- 450
- Registration Number
- NCT03383146
- Locations
- 🇺🇸
Atlanta Diabetes Associates, Atlanta, Georgia, United States
🇺🇸Endocrinology Research Associates, Inc., Columbus, Ohio, United States
🇺🇸Texas Clinical Research Institute, LLC, Arlington, Texas, United States
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01
- Conditions
- GastroparesisDiabetes Mellitus
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-09-18
- Last Posted Date
- 2021-07-29
- Lead Sponsor
- Allergan
- Target Recruit Count
- 336
- Registration Number
- NCT03285308
- Locations
- 🇺🇸
Digestive Health Specialist of the South East, Dothan, Alabama, United States
🇺🇸Aurora Care Clinic, LLC, Costa Mesa, California, United States
🇺🇸Savin Medical Group LLC, Miami Lakes, Florida, United States
Effect of Relamorelin on Satiation, Gastric Volume, Gastric Accommodation and Distal Gastric Function in Healthy Volunteers
- First Posted Date
- 2015-06-09
- Last Posted Date
- 2016-09-22
- Lead Sponsor
- Motus Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT02466711
- Locations
- 🇺🇸
Mayo Clinic - Rochester, Rochester, Minnesota, United States
Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis
- Conditions
- Diabetes MellitusDiabetes Mellitus ComplicationsGastroparesis
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-02-06
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- Allergan
- Target Recruit Count
- 393
- Registration Number
- NCT02357420
- Locations
- 🇺🇸
Syrentis Clinical Research, Santa Ana, California, United States
🇺🇸River Birch Research Alliance LLC, Blue Ridge, Georgia, United States
🇺🇸Gastroenterology Consultants, Virginia Beach, Virginia, United States
Study to Evaluate the Effects of RM-131 in Patients With Chronic Constipation
- First Posted Date
- 2014-05-14
- Last Posted Date
- 2016-09-22
- Lead Sponsor
- Motus Therapeutics, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT02137642
- Locations
- 🇺🇸
Mayo Clinic - Rochester, Rochester, Minnesota, United States
A Phase 2 Study to Evaluate the Safety and Efficacy of RM-131 in Patients With Parkinson's Disease & Chronic Constipation
- First Posted Date
- 2013-10-07
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Motus Therapeutics, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT01955616
- Locations
- 🇺🇸
Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan, United States
🇺🇸Atlantic Neuroscience, Summit, New Jersey, United States
🇺🇸Michigan State University, East Lansing, Michigan, United States
Phase 2 Study to Evaluate Safety and Efficacy of RM-131 Administered to Patients With Chronic Constipation
- First Posted Date
- 2013-01-31
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Motus Therapeutics, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT01781104
- Locations
- 🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic Rochester, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.